‘Rapid’ uptake of CF triple therapy

Sheshtyn Paola 18/11/2025

PBS listing of the combination medicine has led to improved quality of life for patients with cystic fibrosis (CF), says drug utilisation committee Nearly 90% of Australians prescriptions of cystic fibrosis transmembrane conductance regulator (CFTR) modulators in 2024 were for the combination medicine elexacaftor, tezacaftor and ivacaftor, also known as Trikafta. There were 3,126 patients

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

‘Rapid’ uptake of CF triple therapy

Previous dRx series: deprescribing macrogol in older people

Next Seizing the opportunity

MENU

ajp.com.au

Previous dRx series: deprescribing macrogol in older people

Next Seizing the opportunity

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.